Crucell's manufacturing woes could threaten acquisition by J&J
This article was originally published in Scrip
Executive Summary
Johnson & Johnson plans to proceed with its $1.75 billion acquisition of Crucell remain on track, but the situation could change if the Dutch biotech firm's issues at its manufacturing plant in Shingal, South Korea, worsen.